Ask AI
ProCE Banner Activity

Personalized Treatment in EGFR-Mutated NSCLC: Applying the Latest Clinical Evidence to Address Barriers and Improve Quality of Care

Slideset

These downloadable slides highlight agents currently used to manage EGFR-mutated NSCLC across the disease spectrum as well as related toxicities based on evidence from recent clinical trials and expert recommendations.

Released: October 29, 2025

Share

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Val R. Adams, PharmD, FCCP, FHOPA, BCOP, has no relevant financial relationships to disclose.

Kevin Chen, PharmD, MS, BCOP, CPP: consultant/advisor/speaker: Amgen, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Pfizer; researcher: Lilly.